Blue Horseshoe Stocks: QURE Recap & More

uniQure N.V. QURE

We included QURE in our premarket report on Thursday, after the company’s hemophilia gene therapy treatment was advanced to Phase III testing.

What followed was an enormous influx of volume, and two really solid, bullish sessions, advancing from a low of 11.55 on Thursday to a new high of 19.34 on Friday. That works out to a very respectable two-day swing of 67%

It’s the highest PPS QURE has attained since 2015, and the two sessions come in at numbers 1 and 2 highest volume days of all time, so we’d say our alert was timed with absolute precision.


Organovo Holdings, Inc. ONVO

We included ONVO in Friday morning’s extended watchlist, and it also put up a pretty good performance on the day.

From a low of 1.45, the stock traded as high as 1.80 on fairly heavy volume. We’ll want to see the stock continue to establish higher highs and higher lows as it’s coming off of its bottom.


PetMed Express, Inc. PETS

We’d like to signal a post-earnings options idea for PETS this morning, after the company set new records with its Q2 numbers. It’s gapping up significantly in the premarket, and the volume it traded on Friday leading into the release was the highest all month.  We’re going to put the PETS 11/17 $40-50 Calls on watch moving forward.


Extended Watchlist:
TISA, IMNP, LBIX, GEVO, KALV, ATNM, ATOS, XNET

Blue Horseshoe Stocks: INFI Review & More

Infinity Pharmaceuticals, Inc. INFI

The stock with the most notable performance from yesterday morning’s watchlist was definitely INFI, which began trending up in the premarket, and continued its climb throughout the entire session.

The stock traded up from a low of 2.44 to 3.75, which works out to an intraday rise of 54% and it came on roughly 38X its monthly average volume. An early pullback from profit taking this morning would be a likely scenario, but if INFI can find support at a higher point than yesterday’s low, from



AcelRx Pharmaceuticals, Inc. ACRX

After the FDA’s rejecion of the company’s ‘Dsuvia” opioid painkiller, ACRX took a monstrous pounding yesterday down to its lowest price in three months.

As you can see on the chart, it fell all the way down to an area of support it had established back in July. We’ll be interested to monitor this play for a bottom, which could come at any time. Moves generated by FDA news, whether positive or negative, tend to be over-exaggerated and are almost always followed by a course correction.


Inotek Pharmaceuticals Corp ITEK

Here we have an example of being extremely ‘early to the party’ as we sometimes say. We alerted on ITEK back in July, after which point it saw a low of .89. It mostly traded sideways throughout the remainder of the summer, but recently began quite an impressive climb.

This morning, the stock hit news highs of 4.15 in premarket trading on news of a proposed merger with a clinical stage gene therapy company. It may have took a few months to realize, but it works out to an increase of 366%

For an added angle going forward, we’ll also signal the ITEK 10/20 $2.50 Calls for possible daytrades and/or swing trades into next week, and the 11/17 $2.50 & $5.00 Calls for a longer term idea.


Extended Watchlist:
SONS, MARK, HSC, DPW, AKS, CLF, RIG, ATNM, MGEN

Blue Horseshoe Stocks: KOOL, TIF Recaps & More

Endocyte, Inc. ECYT

We initially took notice of ECYT on Monday morning just as the company announced it had completed a worldwide license for its prostate cancer treatment now moving into Phase-3 development.

The stock made a solid 130% rip from 1.63 to 3.75 that morning, but it was only just getting started. Yesterday morning the stock ran hard once again, reaching its peak at a new annual high of 6.55. That puts the total on our two-day observed increased of 302% while volume over the same period has been literally hundreds of times greater than the monthly average prior to Monday’s bombshell PR.


Tiffany & Co. TIF – Options Update

As we were just mentioning yesterday morning, we’ve been tracking the TIF 10/20 $92-93 Calls since the morning of September 28th. TIF stock has maintained its gradual ascent since that time, and with that, we’ve seen the potential gains made off of our ideas grow along with it.

The following ranges represent the lows from the 28th to the highs achieved during yesterday’s session:

$92 Calls – Range: 1.00-2.20 – Max Gain: 120%
$92.50 Calls – Range: .85-2.19  – Max Gain: 158%.
$93 Calls – Range: .83-2.15 – Max Gain: 159%


Cesca Therapeutics Inc. KOOL

After including KOOL in yesterday morning’s watchlist, we watched as the stock made a very nice intraday run on the chart with the help of some positive news.

The U.S. Patent and Trademark Office issued a Notice of Allowance on the company’s patent application for its proprietary method for separating target cells from blood, marrow, and other sources.

That prompted a solid boost from 3.96 to 6.44 on the day, marking an intraday push of 63% which was accompanied by the trading of 223X more shares than the monthly average!


Extended Watchlist:
CATB, RGSE, CAPR, ATNM, VKTX, MNKD, BIOP,  HTBX

Blue Horseshoe Stocks: AVEO Recap & More

AVEO Pharmaceuticals, Inc. AVEO

Swinging back around to discuss AVEO is our top order of business this morning after the stock soared to new highs yesterday. We placed this stock on watch on June 23rd, subsequently mentioning it several times.

On the day of our initial alert, AVEO traded for as little as 1.05 per share, and after multiple weeks in a near-contnual uptrend, the gains have been fantastic. Yesterday AVEO reached new four year highs of 3.19, marking an overall swing of 204%

Volume over the same period has been greatly heightened, and yesterday’s close at 3.15 was a strong one, so even though AVEO has had momentum-mover status for several sessions, we’re going to want to continue to watch it closely.


Inotek Pharmaceuticals, Inc. ITEK

We’re always looking for a good bottom-bouncer, which is why we want to take note of ITEK this morning after disappointing study results on the company’s eye drug sent shares tumbling yesterday.

As we point out on the chart snapshot below, the stock has been beaten back into oversold territory, leaving a big gap on the chart. We’ll place it on watch for the filling of that gap, which from present pricing would spell gains of up to 60%


Extended Watchlist:
ATNM, HK, FOLD, TEUM, JAGX, MSDI, OCUL

Blue Horseshoe Stocks: SFOR Update & More

StrikeForce Technologies, Inc. SFOR

Prior to including it in yesterday morning’s premarket report, our next most recent mentions of SFOR were last Wednesday and Thursday, giving all our readers plenty of time to catch the massive wave of momentum that has now carried the stock to new highs.

At that time we observed a low of .008 in the stock and in the ensuing four sessions it has managed to register higher highs and higher lows each day. The intraday range on the stock yesterday alone was .0134-.022, a solid 64% rip. Measured from last week’s low, we’ve now witnessed an overall upswing of 175% From our all-time observed low on this familiar play (.0036), yesterday’s high marked a 511% jump.

We’ll continue to observe for an extension of the pattern that has been established here, and remain interested as long as the stock maintains support above yesterday’s swing low.


Oroplata Resources, Inc. ORRP

We signaled ORRP for observation in yesterday’s watchlist, and the stock ended up making a really nice run into the close that was good for sizable intraday gains.

We noticed this one in a routine morning scan yesterday, however, as it is a stock that’s been heavily promoted in the past, we’d like to take this opportunity that our interest in it was purely fundamental. We are not connected in any way to any of the promotions/promoters that have ever gone out on this stock.

In terms of the move it made subsequent to yesterday’s mention, we saw ORRP traverse its way from .265 to .405, for a healthy intraday gain of 53% The stock closed just a shade below its high of day, so we’ll certainly be on the lookout for a continuation of momentum into today’s session.


Acorda Therapeutics, Inc. ACOR

The confluence of a newly-recorded annual low, some insider selling, and a sizable gap to the on the chart to the upside have us thinking about a longer-term options idea to correspond with a possible recovery.

The chart still appears to gearing down, so we could see some slight downside before this idea comes to fruition, but we want to signal and begin monitoring now to make sure we’re not late to the party

. We’re going to put a tab on the ACOR 10/18 $23-25 Calls to prepare ourselves for what could be quite a significant rebound once the stock finds a solid level of support from which to launch a rebound.


Extended Watchlist:
GNID, SGBY, PIRS, ARRY, ATNM, NAVB,